AURA BIOSCIENCES

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: $378.4M

Website

Clinical Trials

Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors

Phase 2

Not yet recruiting

Conditions: Eye Cancer
Metastatic Breast Cancer
Lung Cancer

Interventions: Drug: AU-011
Device: SCS Microinjector
Device: Laser

First Posted Date: 2024-10-16

Last Posted Date: 2024-10-17

Lead Sponsor: Aura Biosciences

Target Recruit Count: 24

Registration Number: NCT06643884

Locations: 🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States
🇺🇸
Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸
Massachusetts Eye and Ear, Boston, Massachusetts, United States

and more 6 locations

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Phase 3

Recruiting

Conditions: Ocular Melanoma
Uveal Melanoma
Choroidal Melanoma
Indeterminate Lesions

Interventions: Drug: Bel-sar
Device: Sham Infrared Laser
Device: Suprachoroidal Microinjector
Device: Sham Microinjector
Device: Infrared Laser

First Posted Date: 2023-08-23

Last Posted Date: 2024-12-19

Lead Sponsor: Aura Biosciences

Target Recruit Count: 100

Registration Number: NCT06007690

Locations: 🇺🇸
Nebraska Medicine's Truhlsen Eye Institute, Omaha, Nebraska, United States
🇺🇸
New Jersey Retina Group, Wayne, New Jersey, United States
🇺🇸
Retina Consultants of Alabama, Birmingham, Alabama, United States

and more 43 locations

A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer

Phase 1

Recruiting

Conditions: Non-muscle-invasive Bladder Cancer
Muscle-Invasive Bladder Carcinoma

Interventions: Combination Product: AU-011 in Combination with Medical Laser Adminstration
Combination Product: AU-011 in Combination with Medical Laser Administration
Drug: AU-011

First Posted Date: 2022-08-02

Last Posted Date: 2024-06-12

Lead Sponsor: Aura Biosciences

Target Recruit Count: 21

Registration Number: NCT05483868

Locations: 🇺🇸
Saint John's Cancer Institute, Santa Monica, California, United States
🇺🇸
Urology Associates, P.C., Nashville, Tennessee, United States
🇺🇸
Baylor College of Medicine, Houston, Texas, United States

and more 6 locations

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Terminated

Conditions: Choroidal Melanoma
Indeterminate Lesions

Interventions: Drug: AU-011
Other: Standard of Care

First Posted Date: 2022-03-04

Last Posted Date: 2023-08-09

Lead Sponsor: Aura Biosciences

Target Recruit Count: 2

Registration Number: NCT05266430

Locations: 🇺🇸
University of Wisconsin Dept of Ophthalmology & Visual Sciences, Madison, Wisconsin, United States
🇺🇸
Retina Consultants of Texas, Bellaire, Texas, United States
🇺🇸
Oregon Health & Science University Casey Eye Institute, Portland, Oregon, United States

and more 4 locations

Phase 2 Trial to Evaluate Belzupacap Sarotalocan (AU-011) Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma

Phase 2

Completed

Conditions: Uveal Melanoma
Ocular Melanoma
Choroidal Melanoma

Interventions: Drug: AU-011
Device: Suprachoroidal Microinjector
Device: PDT Laser

First Posted Date: 2020-06-04

Last Posted Date: 2024-08-21

Lead Sponsor: Aura Biosciences

Target Recruit Count: 22

Registration Number: NCT04417530

Locations: 🇺🇸
UCLA Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸
St. Thomas Health / Tennessee Retina, PC, Nashville, Tennessee, United States
🇺🇸
Midwest Eye Institute, Carmel, Indiana, United States

and more 19 locations

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Recruiting

Conditions: Choroidal Melanoma
Indeterminate Lesions of Eye

First Posted Date: 2019-05-07

Last Posted Date: 2023-12-21

Lead Sponsor: Aura Biosciences

Target Recruit Count: 500

Registration Number: NCT03941379

Locations: 🇺🇸
Retina Associates SW, P.C., Tucson, Arizona, United States
🇺🇸
St. Thomas Health / Tennessee Retina, PC, Nashville, Tennessee, United States
🇺🇸
Byers Eye Institute at Stanford University, Palo Alto, California, United States

and more 13 locations

Study in Subjects With Small Primary Choroidal Melanoma

Phase 1

Completed

Conditions: Ocular Melanoma
Uveal Melanoma
Choroidal Melanoma

Interventions: Drug: Light-activated AU-011
Device: Laser Activation

First Posted Date: 2017-02-14

Last Posted Date: 2024-02-01

Lead Sponsor: Aura Biosciences

Target Recruit Count: 57

Registration Number: NCT03052127

Locations: 🇺🇸
UCLA Jules Stein Eye Institute, Los Angeles, California, United States
🇺🇸
Associated Retinal Consultants, PC, Royal Oak, Michigan, United States
🇺🇸
Retina Consultants of Houston, Houston, Texas, United States

and more 10 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy